River & Mercantile Asset Management LLP Sells 32,080 Shares of Eli Lilly And Co (NYSE:LLY)
River & Mercantile Asset Management LLP lowered its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 32.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 66,133 shares of the company’s stock after selling 32,080 shares during the period. River & Mercantile Asset Management LLP’s holdings in Eli Lilly And Co were worth $8,579,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in the stock. BDO Wealth Advisors LLC boosted its position in Eli Lilly And Co by 29.4% during the 4th quarter. BDO Wealth Advisors LLC now owns 2,229 shares of the company’s stock valued at $258,000 after buying an additional 506 shares during the period. Janney Capital Management LLC purchased a new stake in Eli Lilly And Co during the 1st quarter valued at $246,000. Smithfield Trust Co. boosted its position in Eli Lilly And Co by 1.6% during the 1st quarter. Smithfield Trust Co. now owns 7,277 shares of the company’s stock valued at $944,000 after buying an additional 114 shares during the period. Thoroughbred Financial Services LLC boosted its position in Eli Lilly And Co by 1.4% during the 1st quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock valued at $988,000 after buying an additional 105 shares during the period. Finally, FDx Advisors Inc. boosted its position in Eli Lilly And Co by 48.3% during the 4th quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock valued at $2,257,000 after buying an additional 6,356 shares during the period. 79.42% of the stock is currently owned by institutional investors.
In other Eli Lilly And Co news, CFO Joshua L. Smiley purchased 426 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was bought at an average cost of $118.03 per share, with a total value of $50,280.78. Following the transaction, the chief financial officer now directly owns 30,410 shares in the company, valued at approximately $3,589,292.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Donald A. Zakrowski sold 1,000 shares of Eli Lilly And Co stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $128.50, for a total transaction of $128,500.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 246,112 shares of company stock valued at $31,888,255. 0.11% of the stock is currently owned by corporate insiders.
NYSE:LLY opened at $111.74 on Friday. Eli Lilly And Co has a 12 month low of $84.64 and a 12 month high of $132.13. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. The stock has a market capitalization of $108.56 billion, a PE ratio of 20.13, a P/E/G ratio of 1.98 and a beta of 0.27.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.12 billion. During the same period last year, the company posted $1.31 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Friday, May 17th were given a $0.645 dividend. The ex-dividend date of this dividend was Thursday, May 16th. This represents a $2.58 annualized dividend and a dividend yield of 2.31%. Eli Lilly And Co’s dividend payout ratio is 46.49%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Using the New Google Finance Tool
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.